Fully human anti-VEGF antibodies and methods of using
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 10, 2012
Issued Date -
N/A
app pub date -
Oct 20, 2008
filing date -
Oct 22, 2007
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully